EP Patent

EP3888638A1 — Stabilized modified release vitamin d formulation and method of administering same

Assigned to Eirgen Pharma Ltd · Expires 2021-10-06 · 5y expired

What this patent protects

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 . The formulation further comprises an effective amount of a stabilizing agent, and a secondary additive…

USPTO Abstract

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 . The formulation further comprises an effective amount of a stabilizing agent, and a secondary additive comprising one or more compounds from the group consisting of: calcium salts, bisphosphonates, calcimimetics, nicotinic acid, iron, phosphate binders, cholecalciferol, ergocalciferol, active Vitamin D sterols, glycemic control agents, hypertension control agents, antineoplastic agents, and inhibitors of CYP24, inhibitors of cytochrome P450 enzymes that can degrade vitamin D agents. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

Drugs covered by this patent

Patent Metadata

Patent number
EP3888638A1
Jurisdiction
EP
Classification
Expires
2021-10-06
Drug substance claim
No
Drug product claim
No
Assignee
Eirgen Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.